TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Short Interest Update

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) was the recipient of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 89,600 shares, a growth of 71.0% from the December 15th total of 52,400 shares. Approximately 12.9% of the shares of the stock are sold short. Based on an average trading volume of 57,900 shares, the days-to-cover ratio is presently 1.5 days.

TransCode Therapeutics Stock Performance

Shares of RNAZ stock remained flat at $3.35 during mid-day trading on Friday. The stock had a trading volume of 28,766 shares, compared to its average volume of 112,242. The business has a fifty day moving average price of $141.64 and a two-hundred day moving average price of $392.17. TransCode Therapeutics has a 12-month low of $2.66 and a 12-month high of $83.16.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in TransCode Therapeutics stock. Sheets Smith Wealth Management lifted its stake in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ) by 149.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,138 shares of the company’s stock after acquiring an additional 30,000 shares during the quarter. Sheets Smith Wealth Management owned approximately 0.29% of TransCode Therapeutics worth $29,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Analyst Upgrades and Downgrades

Separately, HC Wainwright upped their price objective on shares of TransCode Therapeutics from $3.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.